Why is biotechnology revenue often missing or lumpy?
Many biotech issuers are pre-commercial or recognize collaboration revenue irregularly. Belvedere reports tagged facts and does not fill blanks with peak-sales models.
Industry intelligence
Biotechnology
Public companies in Belvedere's biotechnology universe, with source-linked financials. Valuation multiples are shown only when licensed market data exists.
Is this a ranking of biotech stocks?
No. It is the current mapped universe. Separate rankings require comparable financial facts and a published formula.
Biotechnology mapping follows SIC 2830–2836 where present. Many biotech issuers have lumpy, collaboration, or pre-commercial economics. Missing revenue or free cash flow is shown as unavailable rather than estimated. Clinical-trial success, cash runway in months, and peak-sales models appear only if they are identified in a cited filing or a human-reviewed Belvedere note—not as invented forecasts.
Companies4
Published research0
GeographyUnited States SEC registrants in this extract
Companies
| Company | Ticker | Industry | Revenue | Growth | Belvedere FCF | Latest filing | Research |
|---|---|---|---|---|---|---|---|
| Amphastar Pharmaceuticals, Inc.Nasdaq: AMPH | AMPH | Pharmaceutical Preparations | $183.9M | +5.4% | — | 10-Q · Aug 6, 2026 | Universe |
| Pacira BioSciences, Inc.Nasdaq: PCRX | PCRX | Pharmaceutical Preparations | $192.4M | +6.2% | — | 10-Q · Aug 4, 2026 | Universe |
| PHIBRO ANIMAL HEALTH CORPNasdaq: PAHC | PAHC | Pharmaceutical Preparations | $383.5M | +10.3% | — | 10-K · Aug 26, 2026 | Universe |
| SUPERNUS PHARMACEUTICALS, INC.Nasdaq: SUPN | SUPN | Pharmaceutical Preparations | $219.1M | +32.4% | — | 10-Q · Aug 3, 2026 | Universe |
Research
No Belvedere reports are currently published in this sector.
Research Radar (subset)
- PHIBRO ANIMAL HEALTH CORP (PAHC) — Cash: $61.4M · Cash and cash equivalents were $61.4M as of the latest reported balance-sheet date.
- Amphastar Pharmaceuticals, Inc. (AMPH) — Revenue: +5.4% · Revenue increased +5.4% ($174.4M to $183.9M; Q2 2025 vs Q2 2026).
- Amphastar Pharmaceuticals, Inc. (AMPH) — Revenue acceleration: +5.1 pp · Quarterly revenue YoY growth moved from +0.4% to +5.4% (+5.1 percentage points).
- Amphastar Pharmaceuticals, Inc. (AMPH) — Margin change: $0.508 · Reported gross margin was +50.8% in the latest comparable period.
- Amphastar Pharmaceuticals, Inc. (AMPH) — Cash: $223.6M · Cash and cash equivalents were $223.6M as of the latest reported balance-sheet date.
- Amphastar Pharmaceuticals, Inc. (AMPH) — Share count: $42.5M · Shares outstanding were 42,532,225 as of the latest reported date.
- Pacira BioSciences, Inc. (PCRX) — Revenue: +6.2% · Revenue increased +6.2% ($181.1M to $192.4M; Q2 2025 vs Q2 2026).
- Pacira BioSciences, Inc. (PCRX) — Revenue acceleration: +1.2 pp · Quarterly revenue YoY growth moved from +5.0% to +6.2% (+1.2 percentage points).
Related rankings
- Highest Free Cash Flow Margins
- Strongest Balance Sheets
- Companies With Revenue Growth and Positive Free Cash Flow
- Technology Companies by Revenue Growth
- Healthcare Companies by Revenue Growth
- Industrial Companies by Revenue Growth
Frequently asked questions
- Why is biotechnology revenue often missing or lumpy?
- Many biotech issuers are pre-commercial or recognize collaboration revenue irregularly. Belvedere reports tagged facts and does not fill blanks with peak-sales models.
- Is this a ranking of biotech stocks?
- No. It is the current mapped universe. Separate rankings require comparable financial facts and a published formula.
- Does Belvedere estimate cash runway?
- Cash is shown when tagged. Runway in months requires a spend assumption that is not published unless a dated note states it explicitly.